Friday, 18 Oct 2019

You are here

ANCA Levels Predict Relapse in ANCA-Associated Vasculitis

A team of Japanese investigators examine 126 patients with ANCA-associated renal vasculitis to see if ANCA levels would predict disease relapse.

With a median 41 months of observation, 118 patients achieved remission, and after remission, 34 patients relapsed (21.7%). The risk of relapse was significantly associated with lung involvement (adjusted HR 2.29) and increased ANCA levels (adjusted HR 17.4). The median time from ANCA level increase to relapse was 0.6 months (IQR 0–2.1 mos).

Hence, in this study an increase in ANCA level during remission was associated with a significant risk of disease relapse and may be useful in guiding treatment decisions in patients with ANCA-associated vasculitis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.